Annual report pursuant to Section 13 and 15(d)

Acquisition - Schedule of Assets Acquired and Liabilities Assumed (Details)

v3.20.1
Acquisition - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
Jul. 15, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]        
Total acquired identifiable intangible assets $ 7,300,000      
Goodwill 8,300,000 $ 8,433,000
BioPharma Acquisition [Member]        
Business Acquisition [Line Items]        
Cash 13,829,000      
Subordinated note payable 6,822,000      
Total consideration 20,651,000      
Accounts receivable 3,731,000      
Accrued revenue 289,000      
Lab supplies 877,000      
Prepaid expenses 266,000      
Property and equipment 6,412,000      
Operating lease assets 2,187,000      
Total acquired identifiable intangible assets 7,300,000      
Goodwill 8,273,000      
Total assets acquired 29,335,000      
Accounts payable (4,535,000)      
Accrued liabilities (435,000)      
Deferred revenue (1,076,000)      
Operating lease liabilities (2,187,000)      
Finance lease liabilities (451,000)      
Total liabilities assumed (8,684,000)      
Net assets acquired 20,651,000      
BioPharma Acquisition [Member] | Trademarks and Trade Name [Member]        
Business Acquisition [Line Items]        
Total acquired identifiable intangible assets 1,600,000      
BioPharma Acquisition [Member] | Customer Relationships [Member]        
Business Acquisition [Line Items]        
Total acquired identifiable intangible assets $ 5,700,000